BioSpace News Archive

Drug Development

Regeneron’s REGN-COV2 Cocktail Meets Clinical Endpoints in Phase II/III Trial

The positive findings were shared as part of the company’s Emergency Use Authorization submission for its investigational COVID-19 therapy.

October 30, 2020
·
3 min read
·
Brandon May
Business

Beleaguered Bellicum Slashes 79% of Workforce in Restructuring

Thursday afternoon, Bellicum announced it will pause the development of its BCMA GoCAR-NK program and will also discontinue discovery research and new product development.

October 30, 2020
·
3 min read
·
Alex Keown
AstraZeneca Divests Rights to Two Cardiovascular Drugs for $400 Million

AstraZeneca is divesting two cardiovascular drugs to Germany’s Cheplapharm Arzneimittel GmbH for $400 million, which will allow the UK pharma giant to reinvest in its main therapy areas.

October 30, 2020
·
2 min read
·
Alex Keown
Drug Development

Novo Nordisk Ends Development of NN9828, Shifts Focus to Pandemic Initiatives

Novo Nordisk announced today that it has ended its development of the anti-IL-21 antibody NN9828 in combination with Victoza. The decision was made after analyzing Phase II clinical trial data in patients with Type 1 diabetes.

October 30, 2020
·
2 min read
·
Krystle Vermes
Drug Development

Regeneron Halts Enrollment of Critically Ill Patients in COVID-19 Antibody Trial

The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation.

October 30, 2020
·
3 min read
·
Brandon May
Bio NC

Election Implications for the U.S. and Global COVID-19 Response

The U.S. – and global – response to the COVID-19 pandemic has been volatile at best. This is fair, considering that SARS-CoV-2 is a novel virus with a lethality we haven’t seen in more than a century.

October 30, 2020
·
5 min read
·
Heather McKenzie
BioForest

Clinical Catch-Up: October 26-30

It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.

October 30, 2020
·
14 min read
·
Mark Terry
Drug Development

Halloween Horror: Is it COVID-19 or Another Infection of the Night?

The sound of coughing and gasping breath is coming up fast. A slow look over your shoulder reveals the sweaty, nightmare visage of COVID-19 – or does it?

October 30, 2020
·
3 min read
·
Alex Keown
Business

AbCellera Enters Pact with Kodiak Sciences to Develop Eye Disease Antibodies

AbCellera and Kodiak Sciences have announced a new partnership to create and develop therapeutic antibodies for ophthalmologic indications. The two companies originally entered a partnership in August 2016.

October 30, 2020
·
3 min read
·
Mark Terry
Drug Development

COVID-19 is 6-Fold More Prevalent than Reported Incidents, German Study Says

A seroprevalance study of 15,591 children in Bavaria, published October 28th in Med, revealed a six-fold greater prevalence of the SARS-CoV-2 virus than reported cases.

October 30, 2020
·
4 min read
·
Gail Dutton